Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels:KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product candidate designed to reduce Graft versus Host Disease (GVHD) and relapse after hematopoietic stem cell transplantations (HSCT), today announces that it has received a new debt facility from Kreos Capital providing the Company with up to €20 million of additional financing. This is in addition to the Company’s €15 million debt financing from Kreos Capital in 2017.
Arthur Lahr, CEO of Kiadis Pharma, commented: “This additional agreement with Kreos Capital gives us the option to comfortably extend our cash runway into the first quarter of 2020, with limited dilution, once we have received the anticipated opinion from the CHMP in the fourth quarter of 2018.”
Maurizio PetitBon, General Partner of Kreos Capital, commented:”Kiadis Pharma is advancing treatment in the field of allogeneic hematopoietic stem cell transplantations and has the potential to improve the outcomes of patients suffering from blood cancers. We are proud to extend our relationship with Kiadis Pharma as they enter the next phase to further drive the development of ATIR101.”